Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Gastroenteropancreatic Neuroendocrine Tumor Clear all

Completed Phase 1Phase 2 Interventional

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

NCT02611024

View directory record Official record

Conditions: Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
Interventions: Lurbinectedin, Irinotecan; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older

Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 4
States / cities: Santa Monica, California • Boston, Massachusetts • Houston, Texas

Source: ClinicalTrials.gov public record

Updated Jul 8, 2025 · Synced May 21, 2026, 5:36 PM EDT

Completed No phase listed Observational

Community-based Neuroendocrine Tumor (NET) Research Study

NCT02730104

View directory record Official record

Conditions: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Not listed
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older

Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 12
States / cities: Sedona, Arizona • Denver, Colorado • Arlington Heights, Illinois + 8 more

Source: ClinicalTrials.gov public record

Updated Jun 25, 2020 · Synced May 21, 2026, 5:36 PM EDT

Recruiting Phase 1 Interventional

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

NCT04609592

View directory record Official record

Conditions: Gastroenteropancreatic Neuroendocrine Tumor
Interventions: Lutathera, Gallium 68 Dotatate, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), PET/CT; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older

Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Stanford, California

Source: ClinicalTrials.gov public record

Updated Sep 8, 2025 · Synced May 21, 2026, 5:36 PM EDT

Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752

View directory record Official record

Conditions: Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Interventions: [177Lu]Lu-DOTA-TATE, Octreotide LAR; Radiation · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years

Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 19
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more

Source: ClinicalTrials.gov public record

Updated Apr 29, 2026 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 2 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT00454363

View directory record Official record

Conditions: Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor
Interventions: Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older

Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 3
States / cities: Boston, Massachusetts • Houston, Texas

Source: ClinicalTrials.gov public record

Updated Apr 2, 2020 · Synced May 21, 2026, 5:36 PM EDT

Active, not recruiting Phase 2 Interventional Results available

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

NCT02595424

View directory record Official record

Conditions: Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older

Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 673
States / cities: Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more

Source: ClinicalTrials.gov public record

Updated Apr 30, 2026 · Synced May 21, 2026, 5:36 PM EDT

Active, not recruiting No phase listed Observational

Neuroendocrine Tumors - Patient Reported Outcomes

NCT05064150

View directory record Official record

Conditions: Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm, Neuroendocrine Carcinoma
Interventions: Not listed
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older

Enrollment: 2,539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Gainesville, Florida • Iowa City, Iowa • Kansas City, Kansas + 11 more

Source: ClinicalTrials.gov public record

Updated Dec 17, 2025 · Synced May 21, 2026, 5:36 PM EDT

Recruiting Phase 1Phase 2 Interventional

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

NCT05636618

View directory record Official record

Conditions: Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma, Meningioma
Interventions: [203Pb]VMT-α-NET, [212Pb]VMT-α-NET; Drug
Lead sponsor: Perspective Therapeutics; Industry
Eligibility: 18 Years to 90 Years

Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 19
States / cities: Jacksonville, Florida • Miami, Florida • Chicago, Illinois + 16 more

Source: ClinicalTrials.gov public record

Updated May 13, 2026 · Synced May 21, 2026, 5:36 PM EDT

Active, not recruiting No phase listed Observational

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064

View directory record Official record

Conditions: Neuroendocrine Tumors
Interventions: LUTATHERA; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 18 Years and older

Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • Portland, Ohio • Portland, Oregon + 1 more

Source: ClinicalTrials.gov public record

Updated Dec 22, 2025 · Synced May 21, 2026, 5:36 PM EDT

Terminated Phase 2 Interventional Results available

A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

NCT03670030

View directory record Official record

Conditions: Neuroendocrine Tumors
Interventions: ABI-009; Drug
Lead sponsor: Robert Ramirez; Other
Eligibility: 18 Years and older

Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Source: ClinicalTrials.gov public record

Updated Jun 9, 2021 · Synced May 21, 2026, 5:36 PM EDT

Active, not recruiting Phase 3 Interventional Results available

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT03375320

View directory record Official record

Conditions: Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
Interventions: Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 433
States / cities: Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 290 more

Source: ClinicalTrials.gov public record

Updated Apr 30, 2026 · Synced May 21, 2026, 5:36 PM EDT

Active, not recruiting Phase 2 Interventional Results available

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

NCT04711135

View directory record Official record

Conditions: Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
Interventions: Lutetium [177Lu] oxodotreotide/dotatate; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 12 Years to 17 Years

Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 3
States / cities: Lexington, Kentucky • Cincinnati, Ohio • Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Feb 11, 2026 · Synced May 21, 2026, 5:36 PM EDT

Terminated Phase 2 Interventional Results available

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

NCT03042780

View directory record Official record

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
Interventions: FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF); Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older

Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Source: ClinicalTrials.gov public record

Updated Nov 26, 2020 · Synced May 21, 2026, 5:36 PM EDT

Active, not recruiting Phase 3 Interventional

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226

View directory record Official record

Conditions: Neuroendocrine Tumors
Interventions: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin); Drug · Other
Lead sponsor: ITM Solucin GmbH; Industry
Eligibility: 18 Years and older

Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 14
States / cities: Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more

Source: ClinicalTrials.gov public record

Updated Sep 9, 2025 · Synced May 21, 2026, 5:36 PM EDT

Recruiting Phase 2 Interventional

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

NCT05773274

View directory record Official record

Conditions: Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
Interventions: Biospecimen Collection, Cabozantinib, Computed Tomography, Everolimus, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Sunitinib; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

NCT02955069

View directory record Official record

Conditions: Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
Interventions: PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Duarte, California • Denver, Colorado • Tampa, Florida + 4 more

Source: ClinicalTrials.gov public record

Updated Apr 11, 2021 · Synced May 21, 2026, 5:36 PM EDT

Recruiting Phase 3 Interventional

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

NCT05477576

View directory record Official record

Conditions: GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
Interventions: RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide; Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 32
States / cities: Phoenix, Arizona • Duarte, California • Irvine, California + 27 more

Source: ClinicalTrials.gov public record

Updated Mar 29, 2026 · Synced May 21, 2026, 5:36 PM EDT

Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

NCT04234568

View directory record Official record

Conditions: Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor
Interventions: Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Triapine; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 11
States / cities: Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more

Source: ClinicalTrials.gov public record

Updated Apr 29, 2026 · Synced May 21, 2026, 5:36 PM EDT

Recruiting Phase 1Phase 2 Interventional

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

NCT06427798

View directory record Official record

Conditions: Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
Interventions: 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years

Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2039
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Mar 9, 2026 · Synced May 21, 2026, 5:36 PM EDT

Recruiting Phase 1 Interventional

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727

View directory record Official record

Conditions: Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Interventions: 225Ac-ETN029, 111In-ETN029; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years

Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more

Source: ClinicalTrials.gov public record

Updated May 4, 2026 · Synced May 21, 2026, 5:36 PM EDT

Completed No phase listed Observational

A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly

NCT06253897

View directory record Official record

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
Interventions: Not listed
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Source: ClinicalTrials.gov public record

Updated Dec 23, 2024 · Synced May 21, 2026, 5:36 PM EDT

Active, not recruiting Phase 1 Interventional

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

NCT04750954

View directory record Official record

Conditions: Neuroendocrine Neoplasm
Interventions: Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Peposertib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Duarte, California • Miami, Florida • Lexington, Kentucky + 2 more

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 21, 2026, 5:36 PM EDT

Recruiting Phase 4 Interventional

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

NCT06016855

View directory record Official record

Conditions: Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2
Interventions: Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Copper Cu 64 Dotatate, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Source: ClinicalTrials.gov public record

Updated Dec 16, 2025 · Synced May 21, 2026, 5:36 PM EDT

Completed Phase 2 Interventional

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

NCT02250885

View directory record Official record

Conditions: Carcinoma, Neuroendocrine
Interventions: Selinexor; Drug
Lead sponsor: Gabrail Cancer Center Research; Other
Eligibility: 18 Years and older

Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Canton, Ohio

Source: ClinicalTrials.gov public record

Updated Sep 16, 2019 · Synced May 21, 2026, 5:36 PM EDT